MIF inhibitors(Macrophage migration inhibitory factor inhibitors), PDE10A inhibitors(Phosphodiesterase 10A inhibitors), PDE11A inhibitors(phosphodiesterase 11A inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCardiovascular Diseases+ [7]

Active Indication

AsthmaCerebral HemorrhageCervical myelopathy+ [14]

Inactive Indication

Brain InjuriesCerebral ArteriosclerosisChemotherapy-induced damage+ [10]

Originator Organization

KYORIN Pharmaceutical Co., Ltd.

Active Organization

KYORIN Pharmaceutical Co., Ltd.

The Ohio State University

MediciNova, Inc.

+ [2]

Inactive Organization

VA Office of Research and Development

The New York State Psychiatric Institute

Avigen, Inc.

+ [1]

License Organization

Beijing Xinglin Pharmaceutical Co. Ltd.

MediciNova, Inc.

Drug Highest PhaseApproved

First Approval Date

Japan (01 Jan 1989),

Cerebral Arteriosclerosis

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC14H18N2O

InChIKeyZJVFLBOZORBYFE-UHFFFAOYSA-N

CAS Registry50847-11-5

Clinical Trials associated with Ibudilast

NCT05513560

/ SuspendedPhase 2/3IIT

REcovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM)

The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added.
Interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited across Canada. Results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable Canada to improve the clinical care of patients with Long COVID.

Start Date31 May 2023

Sponsor / Collaborator

University Health Network

NCT04631471

/ RecruitingPhase 3IIT

Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy

Degenerative (wear and tear arthritis of the spine) Cervical (concerning the neck) Myelopathy (injury to the spinal cord), DCM, is the most common spinal cord disorder of adulthood. In DCM, arthritis of the spine causes compression of the spinal cord.
The symptoms of DCM are often mistaken for natural consequences of ageing, including numb and clumsy hands, loss of coordination, imbalance, bladder and bowel problems. The weakness can progress to severe paralysis. Every year approximately 4 individuals in 100,000 undergo surgery for DCM; however, many more individuals are thought to suffer from DCM.
The main treatment for DCM is surgery. The aim of surgery is to create space and remove the compression of the spinal cord. This is known to prevent further injury. Unfortunately, the post-operative improvements are often incomplete and many patients remain severely disabled. Improving outcome after surgery represents an important unmet clinical need.
Clinical and preclinical findings indicate that the drug Ibudilast can stimulate neuroprotective and regenerative processes in the spinal cord. Ibudilast is well-tolerated and used to treat asthma and post-stroke dizziness in Japan and is currently being investigated for use in treating other neurological diseases.
This study will investigate whether daily oral administration of Ibudilast for a maximum of 34 weeks can improve hand function, strength, balance, urinary problems and reduce pain.
The study will initially be conducted at three sites in the UK, with more sites added as necessary. Individuals between 18-80 years old, diagnosed with DCM and scheduled for an operation for the first time will be invited to participate in the trial. The study will entail patient questionnaires and clinical assessments before surgery, shortly after surgery and 3, 6, and 12 months after surgery. Moreover, patients will undergo MRI scans pre-operatively and at 6-months postoperatively to determine whether the treatment was successful.

Start Date22 Dec 2021

Sponsor / Collaborator

Cambridge University Hospitals NHS Foundation Trust

ACTRN12619000566134

/ RecruitingPhase 2IIT

OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

Start Date28 Jan 2021

Sponsor / Collaborator-

100 Clinical Results associated with Ibudilast

100 Translational Medicine associated with Ibudilast

100 Patents (Medical) associated with Ibudilast

336

Literatures (Medical) associated with Ibudilast

01 Nov 2025·Neurology-Neuroimmunology & Neuroinflammation

Angiogenesis and Hypoxia Biomarkers Are Dysregulated in Progressive Multiple Sclerosis

Article

Author: Jain, Rajiv W. ; Koch, Marcus Werner ; Goiko, Maria ; Batty, Nicholas J. ; Camara-Lemarroy, Carlos ; Phillips, Serena ; Ghuman, Mankarman ; Yong, Heather Y.F.

BACKGROUND AND OBJECTIVES:

Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative CNS disorder characterized by a state of "virtual hypoxia." Angiogenesis, one of the main homeostatic responses to hypoxia, has been implicated in the pathophysiology of MS. The study objective was to determine whether angiogenic and hypoxia-related molecules are dysregulated in the serum and CNS of patients with progressive multiple sclerosis (PMS).

METHODS:

Baseline serum samples were obtained from a phase II trial of Ibudilast in PMS (n = 203 analyzed) and matched to healthy controls (n = 53). Participants on previous therapeutics (interferons or glatiramer acetate) were excluded from analysis (n = 131). Angiogenic factors were measured using a commercially available bead-based multiplex assay, and hypoxia biomarkers were measured using a custom bead-based multiplex assay. To interrogate the expression of selected hypoxia and angiogenic markers in the CNS, we analyzed publicly available transcriptomic databases and in-house generated data from normal appearing white matter of 2 SPMS donors and 2 nonneurologic disease controls.

RESULTS:

Circulating markers of hypoxia (such as hypoxia inducible factor-1-a, heme oxygenase-1, and heat shock protein-90) were increased in serum. Conversely, markers of angiogenesis (such as vascular endothelial growth factor-A [VEGF-A], heparin-binding epidermal growth factor, and hepatocyte growth factor) were reduced suggesting a blunting of the angiogenic response. Several of these changes were confirmed in the PMS CNS transcriptome. Lower levels of VEGF-A were associated with disability worsening on the timed-25 foot-walk test at 24 (p = 0.02) and 48 (p = 0.02) weeks and predicted disability worsening (hazard ratio 0.31, 95% CI 0.14-0.69, p = 0.034). Conversely, higher leptin levels trended to predict cognitive worsening on the symbol digit modalities test.

DISCUSSION:

Hypoxia-angiogenesis signals are dysregulated in PMS. Increased hypoxia and an insufficient angiogenic adaptive response may play a role in PMS pathophysiology and be a relevant pathway, both in understanding disease mechanisms and as a possible therapeutic target.

01 Oct 2025·PSYCHONEUROENDOCRINOLOGY

Neuronal TLR4 overexpression in the medial prefrontal cortex is associated with neuroinflammation and depression-like behaviors in ovariectomized rats

Article

Author: Zhou, Yiying ; Wang, Fangmin ; Liu, Huizhen ; Huang, Xiaolei ; Zhang, Yisheng ; Zhou, Wenhua ; Lai, Miaojun ; Hu, Yifang

Growing evidence implicates Toll-like receptor 4 (TLR4) expression in neuroinflammatory processes linked to depression pathogenesis, yet its role in perimenopausal depression remains unexplored. This study investigated concurrent changes in TLR4-related inflammatory mechanisms underlying depression-like behaviors following ovariectomy (OVX), focusing on the medial prefrontal cortex (mPFC). Sucrose preference and forced swim tests were used to assess anhedonia and behavioral despair, respectively. Quantitative analysis of TLR4/MyD88/NF-κB/p65 pathway components, pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and apoptosis marker caspase-3 in the mPFC was conducted via Western blotting, whereas dual immunofluorescence staining mapped TLR4 distribution in neurons and microglia. OVX induced depression-like behaviors, along with upregulation of the TLR4-MyD88-NF-κB signalling axis, increased pro-inflammatory cytokines levels, and higher caspase-3 expression in the mPFC. Dual immunofluorescence colocalisation analysis revealed TLR4 expression in both neurons and microglia, with selective neuronal enrichment post-OVX. Notably, the neuronal TLR4 expression profiles showed parallel alterations in apoptosis markers and cytokines. Intraperitoneal administration of ibudilast, a TLR4 inhibitor, significantly ameliorated depression-like behaviors, attenuated upregulation of the TLR4 pathway, and reduced neuroinflammatory markers in OVX rats. These results demonstrate that OVX induces neuronal TLR4 overexpression, which results in concurrent neuroinflammatory and apoptotic processes underlying depressive phenotypes. These findings support the therapeutic potential of TLR4 inhibitors for perimenopausal depression, particularly by targeting neuron-specific inflammatory cascades.

18 Aug 2025·Cureus Journal of Medical Science

Transcanal Endoscopic Tympanoplasty for the Treatment of Localized Eosinophilic Otitis Media in the Tympanic Cavity: A Report of Two Cases

Article

Author: Takahashi, Satoshi ; Hoshikawa, Hiroshi ; Wake, Kokushi ; Miyashita, Takenori

Eosinophilic otitis media (EOM) is a form of refractory otitis media characterized by eosinophil-dominant, highly viscous middle ear effusion, for which tympanoplasty is generally contraindicated. In patients with well-controlled otorrhea who do not require transtympanic therapy, tympanic membrane closure may significantly improve clinical severity scores and reduce the risk of infection. We report two cases of EOM localized to the mesotympanic and hypotympanic cavities that were successfully treated with transcanal endoscopic tympanoplasty without the use of biologics. In both cases, the procedure improved hearing and severity scores, resolved otorrhea, suppressed infection, and alleviated mucosal irritation in the middle ear. Reconstruction of the tympanic membrane using auricular cartilage helped prevent adhesion to mucosal defect regions in the middle ear. These cases suggest that transcanal endoscopic tympanoplasty may be effective in the absence of complications such as chronic eosinophilic rhinosinusitis in patients with well-controlled otitis media and localized mucosal lesions. This report demonstrates the potential applicability of tympanoplasty in selected patients with EOM, despite traditional contraindications. Furthermore, it highlights the effectiveness of combining three antiallergic agents (ibudilast, montelukast, and cetirizine) in controlling postoperative eosinophilic inflammation.

News (Medical) associated with Ibudilast

24 Sep 2025

·www.globenewswire.com

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

Sept. 22, 2025 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in its Phase 2/3 clinical trial, COMBAT-ALS, evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 patients have been randomized across two treatment arms at multiple clinical sites in the United States and Canada. Patient recruitment is now officially closed. MN-166 (ibudilast) is an orally administered small molecules designed to modulate neuroinflammation and oxidative stress pathways implicated in ALS progression. The COMBAT-ALS study is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy, safety, and tolerability of MN-166 over a 12-month treatment period followed by 6-month open-label treatment period. The trial’s primary endpoint is the Combined Assessment of Function and Survival (CAFS). Secondary endpoints include ALSFRS-R score progression, muscle strength measured by hand-held dynamometry, and quality of life assessments. Top-line data are expected by the end of 2026. MN-166 has previously demonstrated promising results in preclinical models and earlier Phase 1/2 and Phase 2 studies, showing a favorable safety profile and a higher proportion of treatment responders among MN-166-treated patients. The compound has received Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA), as well as Orphan Designation from the European Medicines Agency (EMA). “Completing enrollment in this Phase 2b/3 trial marks a major milestone for our MN-166 program and reflects the dedication of our clinical team and the ALS community,” said Dr. Kazuko Matsuda, Chief Medical Officer of MediciNova. “We are deeply grateful to the patients and families participating in this study and look forward to advancing MN-166 (ibudilast) toward potential regulatory submission.” “ALS remains a devastating disease with limited treatment options,” said Dr. Yuichi Iwaki, President and Chief Executive Officer of MediciNova. “We are hopeful that MN-166 may offer a meaningful therapeutic advance for patients living with ALS.” MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. The content above comes from the network. if any infringement, please contact us to modify.

Orphan DrugFast TrackClinical Result

16 Sep 2025

·www.globenewswire.com

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients has been selected for a poster presentation at 36th International Symposium on ALS/MND to be held December 5-7, 2025 in San Diego, CA. The presentation details are as follows: Paper Number: 228 Title: COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Baseline Characteristics Theme: Clinical Trial and Trial Design About MN-166 (ibudilast) MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS). About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT: David H. Crean, Ph.D.Chief Business OfficerMediciNova, Incinfo@medicinova.com

Phase 2Phase 3

08 Sep 2025

·www.globenewswire.com

MediciNova Provides Shareholder Update on Key Developments

LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), provides a shareholder update recapping important developments for the Company. Standby Equity Purchase Agreement (SEPA) The Company reported the signing of a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months. Under that Agreement, the Company shall have the right, but not the obligation, to sell its common stock in individual transactions – or advances – which will be up to 100% of the daily volume traded of MediciNova’s common stock during the five days immediately prior to the transaction date. The stock will be issued without additional warrants and will be sold to one or more investment funds managed by Yorkville Advisors – in this case the investor – at a purchase price equal to 97% of the market price1. Proceeds from the transactions will be used to further advance R&D programs and for general corporate activities. COMBAT-ALS Trial Patient Target Enrollment Achieved as Other Trials Continue The Company recently announced the successful enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast). MN-166 is currently in development for the treatment of Amyotrophic Lateral Sclerosis (ALS). In parallel, the Company is conducting a large Expanded Access Program (EAP) supported by a $22 million grant from the National Institutes of Health (NIH), which is steadily enrolling patients. The Company is also nearing completion of its Phase 2 clinical trial targeted patient enrollment in hypertriglyceridemia and fatty liver disease due to Type 2 diabetes with its second asset, MN-001 (Tipelukast). Dr. Yuichi Iwaki, MediciNova President and CEO, commented, "These developments are essential to our continued thriving in the market. We have completed our target enrollment of our COMBAT-ALS trial for our lead compound, MN-166. This is a significant development for ALS and may provide hope for the hundreds of thousands of patients who are suffering from the condition. We believe that our trial is among the furthest along in the space, and data from two previous clinical trials have been encouraging. Our cash position continues to afford us ability to amply fund our ongoing programs, and this SEPA agreement provides us with additional flexibility if needed to access capital to further support our R&D initiatives, expand our business, and pursue strategic opportunities in an all equity transaction. We are encouraged by our ongoing progress and look forward to providing additional updates on both our main programs and our partnered non-core programs over the near term and in the coming months.” About MediciNovaMediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. Forward-Looking StatementsStatements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT: David H. Crean, Ph.D.Chief Business OfficerMediciNova, Incinfo@medicinova.com 1 Market price is the lowest daily volume weighted average price (VWAP) of the common stock during the pricing period of three consecutive days commencing on the trading day immediately following the investor’s receipt of an Advance Notice.

Phase 2

100 Deals associated with Ibudilast

External Link

KEGG	Wiki	ATC	Drug Bank
D01385	Ibudilast	R03DC04	DB05266

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Asthma	Japan	KYORIN Pharmaceutical Co., Ltd.	17 Jan 1989
Cerebral Hemorrhage	Japan	KYORIN Pharmaceutical Co., Ltd.	17 Jan 1989
Cerebral Arteriosclerosis	Japan	KYORIN Pharmaceutical Co., Ltd.	01 Jan 1989

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cervical myelopathy	Phase 3	-	MediciNova, Inc.	01 Mar 2022
Amyotrophic Lateral Sclerosis	Phase 3	United States	MediciNova, Inc.	28 May 2020
Amyotrophic Lateral Sclerosis	Phase 3	Canada	MediciNova, Inc.	28 May 2020
Post Acute COVID 19 Syndrome	Phase 2	Canada	MediciNova, Inc.	10 Feb 2023
Alcoholism	Phase 2	United States	University of Pennsylvania	14 Jan 2023
COVID-19	Phase 2	United States	MediciNova, Inc.	11 Jan 2021
Respiratory Distress Syndrome, Acute	Phase 2	United States	MediciNova, Inc.	11 Jan 2021
Methamphetamine dependence	Phase 2	United States	Portland VA Medical Center	01 May 2019
Methamphetamine dependence	Phase 2	United States	VA Office of Research and Development	01 May 2019
Neuroinflammation	Phase 2	United States	VA Office of Research and Development	01 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04057898 (COMBAT-ALS, GlobeNewswire) Manual	Phase 2/3	Amyotrophic Lateral Sclerosis	183	MN-166	pbmhdjlgyn(ryptltnwjs) = Positive correlations were observed between the 6-month and 12-month data for CAFS score (0.71), modified CAFS score (0.70), and ALSFRS-R (0.69). [Note: Values in parentheses are Spearman Rank Correlation coefficients] Positive correlations were also observed for Bulbar score (0.74), Fine motor score (0.71), and Gross motor score (0.67), but not for Respiratory score. [Note: Values in parentheses are Spearman Rank Correlation coefficients] vivyajkesm (euyftorbhn )	Positive	05 Dec 2024
				placebo
NCT03594435 (CTgov)	Phase 2	Alcohol Use Disorder	102	Ibudilast (Ibudilast)	zclmeyhudm(kfnqjzwxvs) = cjwbcahezr fttkcnvupx (jzzgsdpvhx, 34.54664) View more	-	27 Nov 2024
				Placebo oral capsule (Placebo Oral Capsule)	zclmeyhudm(kfnqjzwxvs) = rfypqfxauc fttkcnvupx (jzzgsdpvhx, 34.89305) View more
NCT02714036 (CTgov)	Phase 1/2	Amyotrophic Lateral Sclerosis	35	ibudilast (Regular)	fhigkadnuh(owubnztrbj) = kuburxniyb dutmjgzths (eroputuerk, favbpzaoqu - vnlzmmwqcz) View more	-	24 Sep 2024
				Ibudilast (Flexible)	vqcwxfnvrk = lujgfczdoo cdymsckdqv (yzaxjmrfap, giqqbxenlj - diwdihjegj) View more
NCT03782415 (ASCO2024) Manual	Phase 1/2	Glioblastoma CD74 expression	62	Ibudilast temozolomide	oozonhdbgh(xcmczgrwsk) = Ibudilast 50 mg BID adgwdywlem (dpgtusrkuc )	Positive	24 May 2024
				Ibudilast temozolomide
NCT03782415 (GlobeNewswire) Manual	Phase 2	Glioblastoma First line	62	MN-166+temozolomide	-	Positive	19 Nov 2023
				MN-166+temozolomide (newly diagnosed GBM)	qcsbieqnlc(khmeknagan) = evtfqnwslr hrmajzwxln (bxcsuwmvdb )
MN166-GBM-1201 (SNO2023)	Phase 1/2	Glioblastoma CD3+ \| CD74 \| CD11b ... View more	62	MN-166 and TMZ combination therapy	glhwvllbnr(axcmgupeqz) = hgbeqxzqvv temaurnjpi (xkbmetrwaa )	Positive	10 Nov 2023
NCT04429555 (Corporate Publications) Manual	Phase 2	COVID-19 \| Respiratory Distress Syndrome, Adult	34	MN-166	qbtnzqtctm(qfoizzysyl) = simirmeawr klrqstabuo (uqxtwkribr ) View more	Positive	08 Jun 2022
				Placebo	qbtnzqtctm(qfoizzysyl) = vpxmfddjbb klrqstabuo (uqxtwkribr ) View more
NCT02238626 (IBU-ALS-1201, CTgov)	Phase 2	Amyotrophic Lateral Sclerosis	70	MN-166+riluzole (MN-166)	pceijmzoye = bqypkmtujq zpjquxdluf (ohncuugjop, alokyjiiea - xoryvstism) View more	-	05 Nov 2021
				Placebo (for MN-166)+riluzole (Placebo (for MN-166))	ccdacrzpki(xonmqdwuge) = qjbiaatrvb yvhbrskryj (vzzybtebvt, 3.00)
NCT01982942 (SPRINT-MS, ECTRIMS2021)	Phase 2	Multiple Sclerosis, Chronic Progressive	-	Ibudilast	sqpnzpsxof(sucboxjugi) = jaifsyahnp fetczhkyic (tikladfwcc, 0.20)	-	12 Oct 2021
				Placebo	sqpnzpsxof(sucboxjugi) = umxprzvpqy fetczhkyic (tikladfwcc, 0.20)
NCT03489850 (CTgov)	Phase 2	Alcohol Use Disorder	52	Ibudilast (Ibudilast)	oetclmirjk(ksfljrofse) = riisftavso bikjknhvwy (trpzgyyoxh, 0.55) View more	-	07 Oct 2021
				Placebo (Placebo)	oetclmirjk(ksfljrofse) = hqbtpohtgm bikjknhvwy (trpzgyyoxh, 0.41) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ibudilast

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation